<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936919</url>
  </required_header>
  <id_info>
    <org_study_id>BBLCIP002</org_study_id>
    <nct_id>NCT04936919</nct_id>
  </id_info>
  <brief_title>Pilot Evaluation of Smart vs HERO Broadband Light Treatment for Pigmented Skin Lesions</brief_title>
  <official_title>Pilot Evaluation of Smart vs HERO Broadband Light Treatment for Pigmented Skin Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sciton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effects of Intense Pulsed Broad Band Light for&#xD;
      treatment of pigmented lesions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of improvement in photographs</measure>
    <time_frame>4 weeks</time_frame>
    <description>photographs</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pigmented Lesions</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BroadBand Light</intervention_name>
    <description>Treatment arm will receive Broadband light treatment</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female, 18 years or older&#xD;
&#xD;
          -  Fitzpatrick skin type I-III&#xD;
&#xD;
          -  Has visible signs of moderate to severe skin pigmentation&#xD;
&#xD;
          -  Willing to not use any other procedure(s) in the treatment area during the study, such&#xD;
             as laser- or light-based treatment, non-light-based device treatment such as&#xD;
             radiofrequency or ultrasound, injection of botulinum toxin, collagen, hyaluronic acid&#xD;
             filler or other dermal filler, chemical peel, or surgical procedure&#xD;
&#xD;
          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of&#xD;
             birth control at least 3 months prior to enrollment and during the entire course of&#xD;
             the study, and no plans to become pregnant or to father a child for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or&#xD;
             higher on the treatment area every day for the duration of the study, including the&#xD;
             follow-up period&#xD;
&#xD;
          -  Willing to have digital photographs taken of the treatment area and agree to use of&#xD;
             photographs for presentation, educational or marketing purposes&#xD;
&#xD;
          -  Subject must agree to not make any changes in their skin regimen for the duration of&#xD;
             the study, including the follow-up period&#xD;
&#xD;
          -  Subject must be able to read, understand and sign Informed Consent Form&#xD;
&#xD;
          -  Must be willing to adhere to the treatment and follow-up schedule and post-treatment&#xD;
             care instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fitzpatrick skin type IV-VI&#xD;
&#xD;
          -  Participation in a clinical trial of another device or drug within 6 months prior to&#xD;
             enrollment or during the study.&#xD;
&#xD;
          -  Any type of prior cosmetic treatment to the target area within 3 months of study&#xD;
             participation, such as laser or light-based procedures or surgery.&#xD;
&#xD;
          -  Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal&#xD;
             filler in the target area within 1 week of study participation.&#xD;
&#xD;
          -  History of malignant tumors in the target area.&#xD;
&#xD;
          -  Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large&#xD;
             moles.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Having an infection, dermatitis or a rash in the treatment area.&#xD;
&#xD;
          -  Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,&#xD;
             e.g., uncontrolled hypertension.&#xD;
&#xD;
          -  Suffering from coagulation disorders or taking prescription anticoagulation&#xD;
             medications.&#xD;
&#xD;
          -  History of keloid scarring, hypertrophic scarring or of abnormal wound healing.&#xD;
&#xD;
          -  History of immunosuppression/immune deficiency disorders or currently using&#xD;
             immunosuppressive medications.&#xD;
&#xD;
          -  History of vitiligo, eczema, or psoriasis.&#xD;
&#xD;
          -  History of connective tissue disease, such as systemic lupus erythematosus or&#xD;
             scleroderma.&#xD;
&#xD;
          -  History of seizure disorders due to light.&#xD;
&#xD;
          -  Any use of medication that is known to increase sensitivity to light according to&#xD;
             Investigator's discretion.&#xD;
&#xD;
          -  History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes&#xD;
             zoster (shingles) in the treatment area, unless treatment is conducted following a&#xD;
             prophylactic regimen.&#xD;
&#xD;
          -  History of radiation to the treatment area or undergoing systemic chemotherapy for the&#xD;
             treatment of cancer.&#xD;
&#xD;
          -  History of pigmentary disorders, particularly tendency for hyper- or&#xD;
             hypo-pigmentation.&#xD;
&#xD;
          -  Systemic use of retinoid, such as isotretinoin, or corticosteroid, as applicable,&#xD;
             within 6 months of study participation.&#xD;
&#xD;
          -  Topical use of retinoid, such as isotretinoin, corticosteroid or hydroquinone on the&#xD;
             target area within 1 month of participation.&#xD;
&#xD;
          -  Anytime in life, having have used gold therapy (gold salts) for disorders such as&#xD;
             rheumatologic disease or lupus.&#xD;
&#xD;
          -  Excessively tanned in areas to be treated, or unable/unlikely to refrain from tanning&#xD;
             during the study (for example, subject's occupation requires regular sun exposure).&#xD;
&#xD;
          -  Current smoker or history of smoking within 6 months of study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Swengel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RefinedMD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patel</last_name>
    <phone>6504939155</phone>
    <email>clinicaltrials@sciton.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RefinedMD</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pigmentation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

